AstraZeneca
Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.
This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC. This study is designed as non-comparative. Participants will be randomised to Treatment A or B. In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+. The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd…
INCLUSION CRITERIA: 1. Participant must be ≥ 18 years of age at the time of signing the ICF. 2. Pathologically documented NSCLC that: 1. Has documented non-squamous histology 2. Is TROP2 NMR positive 3. Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue. 3. Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition. 4. The ECOG PS of 0 to 2. 5. Known tumour PD-L1 status…
Treatment A/B: Dato-DXd as IV infusion.
Treatment A/B: Durvalumab as IV infusion
Treatment B: Carboplatin as IV infusion